Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan

被引:23
作者
Beghetti, M. [1 ]
机构
[1] Hop Enfants, Unite Cardiol Pediat, CH-1211 Geneva 14, Switzerland
关键词
bosentan; congenital heart defects; endothelin; paediatrics; pulmonary arterial hypertension; treatment;
D O I
10.1111/j.1365-2362.2006.01681.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by vasoconstriction and progressive remodelling of the pulmonary arterial wall leading to right ventricular failure and death. Idiopathic PAH (IPAH) and PAH associated with congenital heart defects account for the majority of paediatric patients with PAH. During the last few decades, several pharmacological approaches have been introduced, including calcium channel-blockers (CCBs), prostacyclin analogues, endothelin receptor antagonists and, most recently, phosphodiesterase inhibitors. This paper reviews the treatment options available to children with a special focus on the initial experience with bosentan. Although CCBs have been shown to increase survival in IPAH, the beneficial effect appears to be limited to a small number of patients, defined as 'responders' to the vasoreactivity testing. With the availability of prostacyclin (intravenous epoprostenol) and then prostacyclin analogues, the treatment options have increased markedly and particularly in patients who have not responded to conventional therapy. Although epoprostenol has been shown to be efficacious in PAH, the drug is not ideal owing to serious complications arising from the invasive mode of application, particularly in children. Phosphodiesterase-5 inhibitors have also shown beneficial effects. Targeting the endothelin (ET) system with the oral, dual ETA/ETB receptor antagonist, bosentan has been demonstrated to improve the cardiopulmonary haemodynamics, exercise capacity, quality-of-life and survival in adult patients with PAH. Specific ETA antagonists may also present the same beneficial profile. Recent experience with bosentan in paediatric patients with PAH indicates that the results obtained in adult patients may be extrapolated to children, thus offering a safe and effective therapy that is easy to administer.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 72 条
[1]  
AHN HS, 1991, ADV EXP MED BIOL, V308, P191
[2]   Primary pulmonary hypertension - A vascular biology and translational research "work in progress" [J].
Archer, S ;
Rich, S .
CIRCULATION, 2000, 102 (22) :2781-2791
[3]   NITRIC-OXIDE AND CGMP CAUSE VASORELAXATION BY ACTIVATION OF A CHARYBDOTOXIN-SENSITIVE K-CHANNEL BY CGMP-DEPENDENT PROTEIN-KINASE [J].
ARCHER, SL ;
HUANG, JMC ;
HAMPL, V ;
NELSON, DP ;
SHULTZ, PJ ;
WEIR, EK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7583-7587
[4]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[5]   Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension [J].
Barst, RJ ;
Ivy, D ;
Dingemanse, J ;
Widlitz, A ;
Schmitt, K ;
Doran, A ;
Bingaman, D ;
Nguyen, N ;
Gaitonde, M ;
van Giersbergen, PLM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :372-382
[6]   Sitaxsentan therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
Langleben, D ;
Frost, A ;
Horn, EM ;
Oudiz, R ;
Shapiro, S ;
McLaughlin, V ;
Hill, N ;
Tapson, VF ;
Robbins, IM ;
Zwicke, D ;
Duncan, B ;
Dixon, RAF ;
Frumkin, LR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447
[7]   Vasodilator therapy for primary pulmonary hypertension in children [J].
Barst, RJ ;
Maislin, G ;
Fishman, AP .
CIRCULATION, 1999, 99 (09) :1197-1208
[8]   PHARMACOLOGICALLY INDUCED PULMONARY VASODILATATION IN CHILDREN AND YOUNG-ADULTS WITH PRIMARY PULMONARY-HYPERTENSION [J].
BARST, RJ .
CHEST, 1986, 89 (04) :497-503
[9]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[10]   Beraprost therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
McGoon, M ;
McLaughlin, V ;
Tapson, V ;
Oudiz, R ;
Shapiro, S ;
Robbins, IM ;
Channick, R ;
Badesch, D ;
Rayburn, BK ;
Flinchbaugh, R ;
Sigman, J ;
Arneson, C ;
Jeffs, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125